Bimekizumab versus secukinumab continuous maintenance of response at every visit through one year in patients with moderate to severe plaque psoriasis: Post-hoc results from the BE RADIANT phase 3b trial. (2022). SKIN The Journal of Cutaneous Medicine, 6(6), s70. https://doi.org/10.25251/skin.6.supp.70